Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GOSS NYSEAMERICAN:MAIA OTCMKTS:NICXF NASDAQ:QTTB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGOSSGossamer Bio$0.34-4.1%$0.41$0.32▼$3.87$82.24M2.156.11 million shs4.34 million shsMAIAMAIA Biotechnology$1.39$1.49$0.87▼$3.19$84.33M0.21692,444 shs410,852 shsNICXFNicox$0.30$0.30$0.25▼$0.30$20.67M-0.04N/AN/AQTTBQ32 Bio$5.14+2.0%$5.86$1.35▼$8.05$78.77M-0.05320,203 shs262,107 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGOSSGossamer Bio0.00%+6.11%-0.05%-86.15%-68.66%MAIAMAIA Biotechnology0.00%+8.06%+0.75%-33.00%-34.63%NICXFNicox0.00%0.00%0.00%0.00%+20.00%QTTBQ32 Bio0.00%-7.86%-21.00%+19.15%+207.32%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGOSSGossamer Bio$0.34-4.1%$0.41$0.32▼$3.87$82.24M2.156.11 million shs4.34 million shsMAIAMAIA Biotechnology$1.39$1.49$0.87▼$3.19$84.33M0.21692,444 shs410,852 shsNICXFNicox$0.30$0.30$0.25▼$0.30$20.67M-0.04N/AN/AQTTBQ32 Bio$5.14+2.0%$5.86$1.35▼$8.05$78.77M-0.05320,203 shs262,107 shsThe 10 Best AI Stocks to Own in 2026Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGOSSGossamer Bio0.00%+6.11%-0.05%-86.15%-68.66%MAIAMAIA Biotechnology0.00%+8.06%+0.75%-33.00%-34.63%NICXFNicox0.00%0.00%0.00%0.00%+20.00%QTTBQ32 Bio0.00%-7.86%-21.00%+19.15%+207.32%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGOSSGossamer Bio 2.20Hold$5.431,515.65% UpsideMAIAMAIA Biotechnology 0.00N/AN/AN/ANICXFNicox 2.50Moderate BuyN/AN/AQTTBQ32 Bio 2.67Moderate Buy$13.00152.92% UpsideCurrent Analyst Ratings BreakdownLatest NICXF, GOSS, QTTB, and MAIA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026QTTBQ32 Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.004/21/2026GOSSGossamer Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/23/2026GOSSGossamer Bio Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral3/12/2026QTTBQ32 Bio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy3/10/2026QTTBQ32 Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.003/6/2026GOSSGossamer Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $5.003/5/2026GOSSGossamer Bio OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$12.00 ➝ $3.002/25/2026QTTBQ32 Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$13.002/24/2026GOSSGossamer Bio BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Underweight2/24/2026GOSSGossamer Bio Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform2/24/2026GOSSGossamer Bio Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGOSSGossamer Bio$48.47M1.63N/AN/A($0.53) per share-0.63MAIAMAIA BiotechnologyN/AN/AN/AN/A$0.06 per shareN/ANICXFNicox$3.59M5.76N/AN/A$0.05 per share6.00QTTBQ32 Bio$53.74M1.49$1.55 per share3.32$3.41 per share1.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGOSSGossamer Bio-$170.37M-$0.75N/AN/AN/A-351.49%N/A-75.50%5/12/2026 (Estimated)MAIAMAIA Biotechnology-$22.40M-$1.38N/AN/AN/AN/A-797.18%-201.77%5/8/2026 (Estimated)NICXFNicox-$24.23MN/AN/AN/AN/AN/AN/AN/A5/12/2026 (Estimated)QTTBQ32 Bio$29.82M$2.302.23N/AN/AN/A988.60%27.32%5/5/2026 (Estimated)Latest NICXF, GOSS, QTTB, and MAIA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026GOSSGossamer Bio-$0.18N/AN/AN/A$4.61 millionN/A5/12/2026N/ANICXFNicox-$0.4660N/AN/AN/A$3.87 millionN/A5/8/2026Q1 2026MAIAMAIA Biotechnology-$0.18N/AN/AN/AN/AN/A5/5/2026Q1 2026QTTBQ32 Bio-$0.68-$0.54+$0.14-$0.54$39.74 millionN/A3/23/2026Q4 2025MAIAMAIA Biotechnology-$0.13-$0.08+$0.05-$0.08N/AN/A3/17/2026Q4 2025GOSSGossamer Bio-$0.20-$0.21-$0.01-$0.21$7.53 million$13.80 million3/10/2026Q4 2025QTTBQ32 Bio-$1.06$3.65+$4.71$4.58N/A$53.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGOSSGossamer BioN/AN/AN/AN/AN/AMAIAMAIA BiotechnologyN/AN/AN/AN/AN/ANICXFNicoxN/AN/AN/AN/AN/AQTTBQ32 BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGOSSGossamer BioN/A2.642.64MAIAMAIA BiotechnologyN/A1.661.66NICXFNicoxN/AN/AN/AQTTBQ32 Bio0.084.854.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGOSSGossamer Bio81.23%MAIAMAIA Biotechnology5.65%NICXFNicoxN/AQTTBQ32 Bio31.32%Insider OwnershipCompanyInsider OwnershipGOSSGossamer Bio7.20%MAIAMAIA Biotechnology19.81%NICXFNicoxN/AQTTBQ32 Bio40.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGOSSGossamer Bio180234.70 million217.80 millionOptionableMAIAMAIA Biotechnology960.67 million48.65 millionNot OptionableNICXFNicox2868.92 millionN/ANot OptionableQTTBQ32 Bio3915.63 million9.38 millionN/ANICXF, GOSS, QTTB, and MAIA HeadlinesRecent News About These CompaniesQ32 Bio's (QTTB) Buy Rating Reaffirmed at HC WainwrightMay 5 at 12:59 PM | marketbeat.comQ32 Bio (NASDAQ:QTTB) Announces Earnings Results, Beats Estimates By $0.14 EPSMay 5 at 12:05 PM | marketbeat.comQ32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 5 at 6:59 AM | prnewswire.comQ32 Bio (QTTB) Expected to Announce Quarterly Earnings on ThursdayApril 30, 2026 | marketbeat.comQ32 Bio (NASDAQ:QTTB) Trading Down 3.8% - What's Next?April 30, 2026 | marketbeat.comQ32 Bio Expands ATM Offering With New $75M ProspectusApril 24, 2026 | tipranks.comQ32 Bio Inc. Common Stock (QTTB) Insider ActivityApril 18, 2026 | nasdaq.comQ32 Bio to Participate in the 25th Annual Needham Virtual Healthcare ConferenceApril 8, 2026 | prnewswire.comQ32 Bio (NASDAQ:QTTB) Shares Up 4.6% - Should You Buy?April 8, 2026 | marketbeat.comDoes Q32 Bio (QTTB) Have the Potential to Rally 97.66% as Wall Street Analysts Expect?March 30, 2026 | zacks.comQ32 Bio: Bempikibart Keeps The Alopecia Areata Bull Case AliveMarch 30, 2026 | seekingalpha.comBest Momentum Stocks to Buy for March 27thMarch 27, 2026 | zacks.comNew Strong Buy Stocks for March 27thMarch 27, 2026 | zacks.comQ32 Bio (QTTB) Upgraded to Strong Buy: Here's What You Should KnowMarch 19, 2026 | zacks.comBest Momentum Stocks to Buy for March 19thMarch 19, 2026 | zacks.comNew Strong Buy Stocks for March 19thMarch 19, 2026 | zacks.comBest Momentum Stocks to Buy for March 13thMarch 13, 2026 | zacks.comWall Street Analysts See a 103.55% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?March 13, 2026 | zacks.comNew Strong Buy Stocks for March 13thMarch 13, 2026 | zacks.comQ32 Bio Faces Governance Backlash and Rising Costs After 2025 Stock Option RepricingMarch 11, 2026 | tipranks.comQ32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate UpdateMarch 10, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNICXF, GOSS, QTTB, and MAIA Company DescriptionsGossamer Bio NASDAQ:GOSS$0.34 -0.01 (-4.11%) Closing price 04:00 PM EasternExtended Trading$0.34 +0.00 (+0.60%) As of 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.MAIA Biotechnology NYSEAMERICAN:MAIA$1.39 0.00 (0.00%) Closing price 04:10 PM EasternExtended Trading$1.38 -0.01 (-0.72%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.Nicox OTCMKTS:NICXF$0.30 0.00 (0.00%) As of 05/1/2026Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. The company is also developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was incorporated in 1996 and is headquartered in Valbonne, France.Q32 Bio NASDAQ:QTTB$5.14 +0.10 (+1.98%) Closing price 04:00 PM EasternExtended Trading$5.08 -0.06 (-1.26%) As of 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
